Exchange: NASDAQ·Updated 07:30 PM EDT

CTKB News

News
all
press releases
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
Zacks
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -150.00% and +1.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
Zacks
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday
Cytek Biosciences (NASDAQ:CTKB) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cytek-biosciences-inc-stock...
MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Recommendation of "Hold" from Analysts
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have been assigned an average rating of "Hold" from the six ratings firms that are covering the stock, Marketbeat.com reports. Two...
MarketBeat

Advertisement|Remove ads.